Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.
Ruta Rao, MD
Advertisement
Articles by Ruta Rao, MD
Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.
Segment 1 establishes the current treatment landscape for HER2-positive metastatic breast cancer (mBC) and highlights key unmet clinical needs.
Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.
CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5